Juan Zafra, Juan Luis Onieva, Javier Oliver, María Garrido-Barros, Andrea González-Hernández, Beatriz Martínez-Gálvez, Alicia Román, Rafael Ordóñez-Marmolejo, Elisabeth Pérez-Ruiz, José Carlos Benítez, Andrés Mesas, Andrés Vera, Rodolfo Chicas-Sett, Antonio Rueda-Domínguez, Isabel Barragán
Up to 80% of patients under immune checkpoint inhibitors (ICI) face resistance. In this context, stereotactic ablative radiotherapy (SABR) can induce an immune or abscopal response. However, its molecular determinants remain unknown. We present early results of a translational study assessing biomarkers of response to combined ICI and SABR (I-SABR) in liquid biopsy from oligoprogressive patients in a prospective observational multicenter study. Cohort A includes metastatic patients in oligoprogression to ICI maintaining the same ICI due to clinical benefit and who receive concomitant SABR...
April 20, 2024: International Journal of Molecular Sciences